Previous studies from these authors have shown that neurons in the brain of a mouse, which lacks the classical estrogen receptor (ER-␣), are capable of binding estrogen. In one region of the mouse hypothalamus that binds estrogen, the preoptic area, the authors have also shown that a variety of estrogenic compounds modulate the expression of a well-known estrogen-regulated gene. Recently, a second estrogen receptor (ER-␤) was isolated from the rat prostate. Interestingly, they have demonstrated that ER-␤ mRNA is present in the same region of the preoptic area where estrogen binding and gene regulation was observed. Together, the results of these studies suggest the presence and functionality of a non-classical estrogen receptor in the mouse brain which lacks ER-␣ and provide evidence that this receptor is ER-␤. Moreover, the localization of ER-␤ mRNA in several brain regions, including those associated with learning and memory, may provide new insight about the role of estrogen in the regulation of brain functions not related to reproduction.
IMMEDIATE COMMUNICATION
Association of an X-chromosome dodecamer insertional variant allele with mental retardation RA Philibert, BH King, S Winfield, EH Cook, Y-H Lee, B Stubblefield, P Damschroder-Williams, C Dea, A Palotie, C Tengstrom, BM Martin, EI Ginns X-Chromosome linked mental retardation affects approximately one in 300 males. Although the genetic causes for some of these cases have been discovered, the causes for the majority of the cases remain unidentified. In this article, the authors demonstrate the strong association of a 12-bp mutation in the coding portion of a newly described X-chromosome gene with X-linked mental retardation in several independent populations. Overall, this mutation was found in 7% of all institutionalized mentally retarded males surveyed. It was also found in higher frequency than expected in a group of males with autism. Although it is not certain, the syndrome observed in these patients may result from the insertion of four amino acids into a region of this newly discovered gene that may have a role in neurodevelopment. Further studies are in progress to understand the relationship of this new mutation to mental retardation. Blackwood and co-workers have described a family segregating manic depression which gives strong evidence for genetic linkage to the short arm of chromosome 4. The authors of this study have also obtained supportive evidence for linkage in the same region. One family in particular appears to show linkage at this locus. However, a discrepancy exists since this study examined fulfilling criteria for a linkage study of schizophrenia while Blackwood et al examined families included in a genetic linkage study of manic depression. This may be explained by the clinical features displayed by members of the families studied by Asherson et al, which show that all the affected members have some symptoms of manic depression. It is therefore possible that a broad phenotype including major depression, manic depression and schizophrenia accompanied by significant mood symptoms can result from mutations within a gene on chromosome 4.
Large CAG/CTG repeats are associated with childhood-onset schizophrenia CE Burgess, K Lindblad, E Sidransky, Q-P Yuan, RT Long, T Breschel, CA Ross, M McInnis, P Lee, EI Ginns, M Lenane, S Kumra, L Jacobsen, JL Rapoport, M Schalling Previous studies of neuropsychiatric disorders have identified an association between schizophrenia and trinucleotide repeat expansions (TREs). Childhoodonset schizophrenia (COS) is a severe variant of schizophrenia with onset of psychotic symptoms prior to age 12 years. Children meeting DSM-IIIR criteria for schizophrenia and showing a resistance to typical neuroleptics were analyzed for TREs using the Repeat Expansion Detection (RED) method. An increased incidence of large CAG/CTG repeats was found in this population confirming previous findings which identified an association between adult onset schizophrenia and TREs. However, in contrast with some previous studies, the association of large repeats with the COS sample seems confined to the male population. Further studies will need to be performed to confirm these results.
A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics AK Malhotra, D Goldman, C Mazzanti, A Clifton, A Breier, D Pickar
The neurotransmitter serotonin has been implicated in the pathophysiology of psychosis. The serotonin transporter (5-HTT) plays a critical role in regulation of serotoninergic function. A recently identified polymorphism in the promoter region of the 5-HTT gene (5-HTTLPR) produces significant differences in 5-HTT expression and function. The authors investigated whether 5-HTTLPR is associated with psychosis by genotyping 50 schizophrenic or schizoaffective patients at 5-HTTLPR and conducting double-blind Brief Psychiatric Rating Scale (BPRS) ratings while the patients were neuroleptic-free. Patients with the 5-HTTLPR ll genotype had significantly higher BPRS ratings for psychosis than patients with the ls or ss genotypes. Examination of individual items revealed a specific significant increase in intensity of hallucinations in patients with the 5-HTTLPR ll genotype. These data provide preliminary evidence for a role of serotonin in the pathophysiology of hallucinations and may represent the identification of an allelic variant that modifies the complex clinical presentation of schizophrenia. Anatomical, pharmacological and human post-mortem studies suggest the dopamine D 3 receptor (DRD3) gene as a candidate for drug dependence. The authors performed an association study of Bal I polymorphism at the DRD3 gene, including 54 opiate addicts and 70 controls. There were no marked differences in genotypes between patients as a whole and controls. However, patients with a sensation-seeking score over 24 (on the Zü ckerman scale) were more frequently homozygotes for both alleles than patients with a sensation-seeking score under 24, or controls. Although obtained in a sample of limited size, these results suggest that the DRD3 gene may have a role in drug dependence susceptibility in individuals with high sensation-seeking scores. This hypothesis is consistent with the role of DRD3 in mediating responses to drugs of abuse in animals and the association of Bal I polymorphism with drug abuse in schizophrenic patients.
Dopamine D 3 receptor gene variants and substance abuse in schizophrenia MO Krebs, F Sautel, M-C Bourdel, P Sokoloff, J-C Schwartz, J-P Olié , H Lô o, M-F Poirier
The dopamine receptor D 3 (DRD3) is thought to be implicated in the pathophysiology of both schizophrenia and pharmacodependence, and is a target for antipsychotics. In an association study in a French Caucasian population, the positive association between homozygosity for Bal I polymorphism in DRD3 gene and schizophrenic was not replicated. However, the homozygosity was significantly more frequent in schizophrenic patients with lifetime substance abuse comorbidity as compared to patients with no history of substance abuse or to controls and neuroleptic responder patients, as compared to treatment refractory patients. The combined characteristics of treatment response and lifetime substance abuse were strongly associated with homozygosity. The authors propose that homozygosity for the Bal I polymorphism of DRD3 is associated with predisposition to substance abuse and/or the pharmacosensitive characteristic of schizophrenia rather than with schizophrenia itself, in agreement with the positive association reported in opiate dependence by Duaux et al.
Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder G Kirov, KC Murphy, MJ Arranz, I Jones, F McCandles, H Kunugi, RM Murray, P McGuffin, DA Collier, MJ Owen, N Craddock
Catechol-O-methyltransferase (COMT) plays a major role in the breakdown of catecholamines. An amino acid polymorphism (val-108-met) determines high and low activity of the enzyme. A recent study of patients with velo-cardio-facial syndrome who had bipolar affective disorder suggested that the Met (low activity) COMT allele might be associated with rapid-cycling in this population. The authors examined whether the low activity allele might be associated with rapid cycling bipolar disorder in the wider population. From a sample of 755 British Caucasian DSM-IV bipolar patients, they selected 55 patients who met criteria for rapid cycling at some time during the illness and 110 who met stringent criteria for a definite non-rapid cycling course. The low activity allele was more frequent in the group of rapid cyclers: 0.55 vs 0.42. The study supports the hypothesis that variation in the COMT gene modifies the course of bipolar disorder.
Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catecholamine-Omethyltransferase allele DF Papolos, S Veit, GL Faedda, T Saito, HM Lachman
Manic depression is a recurrent illness with episodic depressions and periods of irritability or elation. Great variability has been observed in the frequency of episodes, from regular seasonal occurrences to those with distinct shifts of mood and activity that occur within a 24-48 h period. The authors found that individuals with 24-48 h 'ultradian' cycling pattern share a common genetic variation of the catechol-O-methyltransferase (COMT) gene. The protein product of the COMT gene is an enzyme that regulates norepinephrine and dopamine breakdown in the brain. This confirms a recent report by these authors of a strong association in the general population between velo-cardio-facial syndrome patients diagnosed with rapid-cycling bipolar disorder, and the low activity COMT allele. Taken together, these findings suggest that an increase in catecholamine neurotransmission, caused by low COMT activity may be associated with a greater propensity to rapidly switch from depressive to hypomanic episodes, and thereby produce the susceptibility to develop an unstable ultra-ultra rapid form of bipolar disorder.
Effects of fluoxetine on wild and mutant neuronal ␣ 7 nicotinic receptors L Maggi, E Palma, R Miledi, F Eusebi
Fluoxetine is used in the treatment of a variety of clinical disorders including depression and obesity. It is believed to exert its clinical effects because it selectively blocks 5-hydroxytryptamine (5HT) reuptake into nerve terminals. In this study, the authors describe that fluoxetine antagonized the neuronal homomeric ␣ 7 nicotinic acetylcholine receptors (nAChR) expressed in Xenopus oocytes. A similar block occurred in oocytes expressing L247T ␣ 7 mutant nAChR. Cell-attached single channel recordings in oocytes expressing L247T ␣ 7 mutant nAChR showed that the voltage-dependence of the blockage by fluoxetine could be due to a drastic decrease in channel opening frequency accompanied by marked channel flickering and reduced channel conductance. The authors concluded that fluoxetine behaves as a reversible blocker of both wild and mutant ␣ 7 receptors; and that the Leu-247T mutation in the channel domain renders the blockage of ␣ 7 nAChR by fluoxetine voltage-dependent. Glutamine synthetase (GS) which catalyses glutamine synthesis from glutamate and ammonia using ATP is present in all mature glial cells. However, it is unknown whether GS is expressed in glial progenitor cells. Moreover, GS expression levels among the various types of glial cells have never been compared in vitro. To determine when and where GS is expressed in the glial cell lineage, the authors investigated the expression of GS in cultures of either O-2A progenitor cells, type-2 astrocytes, type-1 astrocytes and oligodendrocytes (OL). The results show that GS is present in O-2A progenitor cells, is expressed at different levels in each cultured glial cell type and is also stimulated during OL maturation. Thus, the GS gene, expressed in O-2A progenitor cells, is regulated in a developmental and macroglial cell type-specific manner.
Oligodendrocyte-type-2 astrocyte (O-
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Cloning of rat brain interleukin-18 cDNA AC Culhane, MD Hall, NJ Rothwell, GN Luheshi
Interleukin-1 (IL-1) is involved in the host's response to infection and injury and has been implicated in neurodegeneration. Two forms of IL-1 (␣ and ␤) exist, and recently reports have talked of a new cytokine, interleukin-18 (IL-18) which shares structural homology with IL-1␤, and could therefore potentially mimic actions of IL-1 in the brain. The authors have cloned IL-18 from rat brain and report that recombinant rat pro-IL-18 is processed to its mature 18-kDa form by the enzyme, caspase-1 which cleaves IL-1␤. IL
